Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy

Hepatology Research

Volumn 44, Issue 14, 2014, Pages E397-E407

  Nishikawa, Hiroki ^a   Enomoto, Hirayuki ^c   Nasu, Akihiro ^a   Aizawa, Nobuhiro ^c   Saito, Masaki ^c   Tamori, Akihiro ^b   Kawada, Norifumi ^b   Kimura, Toru ^a   Osaki, Yukio ^a   Nishiguchi, Shuhei ^c  

^a OSAKA RED CROSS HOSPITAL   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Chronic hepatitis C; Histology; IL28B; Interferon gamma inducible protein 10; Telaprevir; Treatment response

Indexed keywords

EID: 84917672675     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12326     Document Type: Article

References (36)

1. Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 2012; 12: 717-728.
2. Imai Y, Tamura S, Tanaka H etal. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat 2010; 17: 185-191.
3. Arase Y, Ikeda K, Suzuki F etal. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50: 16-23.
4. Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013; 4: 635-643.
5. McHutchison JG, Everson GT, Gordon SC etal. PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
6. Hézode C, Forestier N, Dusheiko G etal. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
7. McHutchison JG, Manns MP, Muir AJ etal. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
8. Jacobson IM, McHutchison JG, Dusheiko G etal. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
9. [No authors listed]. Abstracts of the American Association for the Study of Liver Diseases 61st Annual Meeting and Postgraduate Course. October 29-November 2, 2010. Boston, Massachusetts, USA. Hepatology 2010; 52 (Suppl): 320A-1291A.
10. Zeuzem S, Andreone P, Pol S etal. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
11. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
12. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
13. Furusyo N, Ogawa E, Nakamuta M etal. Kyushu University Liver Disease Study (KULDS) Group. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59: 205-212.
14. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010; 52: 421-429.
15. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-621.
16. Grebely J, Feld JJ, Applegate T etal. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology 2013; 57: 2124-2134.
17. Diago M, Castellano G, García-Samaniego J etal. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006; 55: 374-379.
18. Lagging M, Romero AI, Westin J etal. DITTO-HCV Study Group. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44: 1617-1625.
19. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 2009; 200: 1774-1780.
20. Harvey CE, Post JJ, Palladinetti P etal. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74: 360-369.
21. Zeremski M, Petrovic LM, Chiriboga L etal. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440-1450.
22. Askarieh G, Alsiö A, Pugnale P etal. Systemic and intrahepatic interferon-gamma-inducible protein 10kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010; 51: 1523-1530.
23. Kurelac I, Lepej SZ, Grlgic I etal. Chemokine CXCL10 at week 4 of treatment predicts sustained virological response in patients with chronic hepatitis C. J Interferon Cytokine Res 2012; 32: 386-391.
24. Han H, Noureddin M, Witthaus M etal. Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. J Hepatol 2013; 59: 957-963.
25. Romero AI, Lagging M, Westin J etal. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194: 895-903.
26. Darling JM, Aerssens J, Fanning G etal. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011; 53 (1): 14-22.
27. Matsuura K, Watanabe T, Iijima S etal. Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. Hepatol Res 2013; [Epub ahead of print].
28. Bedossa P, Poynald T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996; 24: 289-293.
29. Hara T, Akuta N, Suzuki F etal. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. J Med Virol 2013; 85: 1746-1753.
30. Akuta N, Suzuki F, Sezaki H etal. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48: 372-380.
31. Chen J, Florian J, Carter W etal. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-1455.
32. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: June 10-12, 2002. Hepatology 2002; 36 (Suppl): S3-20.
33. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.
34. Lagging M, Askarieh G, Negro F etal. DITTO-HCV Study Group. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6: e17232.
35. Asahina Y, Tsuchiya K, Tamaki N etal. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518-527.
36. Fattovich G, Covolo L, Bibert S etal. ITAHEC Study Group. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162-1172.